About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research in Urology group is interested in the study of hormone-dependent cancers, in particular prostate cancer (but not limited to it).
Our efforts are focused on finding, on the one hand, tools that help us in the early diagnosis of the disease, in the best differentiation of tumors according to their aggressiveness and their response to therapy, and finally in finding effective therapies against it.
From a molecular point of view, we focus our studies mainly on cell signaling processes related to the cell cycle and mitosis (with kinesins, kinases and ubiquitin ligases as main targets).
Our multidisciplinary group is made up of molecular biologists and urologists, and we collaborate with oncologists, pathologists and specialists in other diseases when required.
We work with in silico data obtained with different "omics" techniques, samples and clinical data from patients, in vitro and in vivo models, to answer the questions raised.
This research line evaluates better strategies able to improve the process of Early Diagnosis of Prostate Cancer, detecting significant tumors and avoiding unnecessary biopsies. In addition, this line also studies the outcomes of the Active Surveillance Program and the Robotic Program.
IP: Joan Morote Robles, Ana Celma Domènech
Since the prostate is in direct contact with the urethra, desquamated cells and secreted products, including exosomes, are abundant in human urine and serve as potential source for PC biomarkers. We aim to identify protein biomarkers in urinary exosomes for early detection of PC in a non-invasive manner.
IP: -
This is a research and teaching line in porcine model of laparoscopy. The influence of pneumo-peritoneum and ischemia in kidney function has been main objectives in the past. Now, the use of bioengineering materials in bladder substitution is the main objective of this line.
IP: Carles Xavier Raventós Busquets
One main objective is the optimization of androgen suppression and to know its safety profile, specifically in the areas of bone mass loss, the metabolic disturbances and cognitive performance. How to perform early diagnosis of CRPC, and how to follow up the new treatments are also objectives of this line.
IP: Jacques Planas Morin
IP: Santiago Ramon y Cajal Agüeras Collaborators: Inés de Torres Ramirez, Jordi Temprana Salvador, Vicente Peg Camara, Stefan Hummer Funding agency: Fundació Institut Bioenginyeria de Catalunya Funding: 0.01 Reference: M6871 Duration: 02/01/2023 - 31/12/2024
IP: Concepción Gomez Gavara Collaborators: Ramon Charco Torra, Ernest Hidalgo Llompart, Enric Miret Alomar, Elizabeth Pando Rau Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 01236 Duration: 01/01/2022 - 30/06/2025
IP: Joan Morote Robles Collaborators: Fernando Lozano Palacio, Inés de Torres Ramirez, Enric Trilla Herrera, Olga Méndez Fernández, Ana Celma Domènech, Mercè Cuadras Solé, Carlos Serrano Burgos, Albert Carrión Puig , Enric Miret Alomar, Maria Eugenia Semidey Raven, Carles Xavier Raventós Busquets, David Ruiz Casajuana, Jacques Planas Morin, Richard Mast, Anna Santamaria Margalef Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00858 Duration: 01/01/2022 - 30/06/2025
IP: - Collaborators: Beatriz Lobo Alvarez, Merce Albert Bayo, Inés de Torres Ramirez, Ana Maria Gonzalez Castro, Marc Pigrau Pastor, Xavier Serra Ruiz Funding agency: Instituto de Salud Carlos III Funding: 183920 Reference: PI19/01643 Duration: 01/01/2020 - 30/06/2024
PMID: 37334020 Journal: BJUI compass Year: 2023 Reference: BJUI Compass. 2023 Mar 7;4(4):420-422. doi: 10.1002/bco2.230. eCollection 2023 Jul. Impact factor: Publication type: Paper in international publication Authors: Abascal, Jose M; Borque-Fernando, Angel; Esteban, Luis M; Mendez, Olga; Morote, Juan; Planas, Jacques; Servian, Pol; Tilla, Enrique; Triquell, Marina et al. DOI: 10.1002/bco2.230
PMID: 37441350 Journal: European urology open science Year: 2023 Reference: Eur Urol Open Sci. 2023 May 22;53:46-54. doi: 10.1016/j.euros.2023.03.013. eCollection 2023 Jul. Impact factor: Publication type: Paper in international publication Authors: Abascal, Jose M; Borque-Fernando, Angel; Campistol, Miriam; Esteban, Luis M; Mendez, Olga; Morote, Juan; Planas, Jacques; Servian, Pol; Trilla, Enrique; Triquell, Marina et al. DOI: 10.1016/j.euros.2023.03.013
PMID: 37444589 Journal: Cancers Year: 2023 Reference: Cancers (Basel). 2023 Jul 3;15(13):3479. doi: 10.3390/cancers15133479. Impact factor: Publication type: Review in international publication Authors: Aguilar, Adriana; Morote, Juan; Planas, Jacques; Trilla, Enrique et al. DOI: 10.3390/cancers15133479
PMID: 37444439 Journal: Cancers Year: 2023 Reference: Cancers (Basel). 2023 Jun 24;15(13):3329. doi: 10.3390/cancers15133329. Impact factor: Publication type: Review in international publication Authors: Catala, Violeta; Morote, Juan; Paesano, Nahuel; Tcholakian, Larisa; Trilla, Enric et al. DOI: 10.3390/cancers15133329
PMID: 35795075 Journal: European Urology Open Science Year: 2022 Reference: Eur Urol Open Sci. 2022 Jul 1;42:40-41. doi: 10.1016/j.euros.2022.06.002. eCollection 2022 Aug. Impact factor: 0 Publication type: Letter whit IF Authors: Trilla, Enrique; Esteban, Luis M; Triquell, Marina; Morote, Juan; Borque-Fernando, Angel et al. DOI: 10.1016/j.euros.2022.06.002
PMID: 35417652 Journal: JOURNAL OF MEDICINAL CHEMISTRY Year: 2022 Reference: J Med Chem. 2022 Apr 28;65(8):6070-6087. doi: 10.1021/acs.jmedchem.1c01941. Epub 2022 Apr 13. Impact factor: 7.446 Publication type: Paper in international publication Authors: Alarcon, Helena, Slobodnyuk, Konstantin, Cano-Galietero, Marta, Fuentes, Pedro, Guijarro, Pedro J, Munoz, Maria Jose, Suarez-Cabrera, Leticia, Santamaria, Anna, Estrada-Tejedor, Roger, Borrell, Jose I et al. DOI: 10.1021/acs.jmedchem.1c01941
PMID: 35366849 Journal: BMC CANCER Year: 2022 Reference: BMC Cancer. 2022 Apr 2;22(1):357. doi: 10.1186/s12885-022-09355-0. Impact factor: 4.43 Publication type: Review in international publication Authors: Planas, Jacques, Celma, Ana, Regis, Lucas, de Torres, Ines M, Semidey, M Eugenia, Trilla, Enrique, Morote, Juan, Cuadras, Merce et al. DOI: 10.1186/s12885-022-09355-0
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control.
A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.
